Drugs / CDP1
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04739111 | Jan 2021 → Sep 2022 | cancer | Dragonboat Biopharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT04151810 | Dec 2019 → Oct 2022 | — | Dragonboat Biopharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT03491709 | Jul 2018 → Sep 2019 | colorectal cancer | Dragonboat Biopharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT03881787 | Apr 2017 → Aug 2019 | — | Dragonboat Biopharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDP1 | “Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)” NCT03881787 ↗ |
| Modality | Monoclonal antibody | “recombinant anti-EGFR human mouse chimeric monoclonal antibody” NCT03491709 ↗ |
| Route | Intravenous | “CDP1, IV, once a week, 250mg/m2” NCT03491709 ↗ |
| Target | EGFR | “anti-EGFR human mouse chimeric monoclonal antibody” NCT03491709 ↗ |